Evang. Krankenhaus Kalk   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Köln Germany

Organization Overview

First Clinical Trial
2005
NCT00449722
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Evangelisches Krankenhaus Kalk, Cologne, Germany | Evang. Krankenhaus Kalk, Medical department | Evang. Krankenhaus Kalk, Medical Department

Active Ingredients

Drugs in Phase 3 Trials (1)

mesalamine (rowasa) (4 trials)

Drugs in Phase 2 Trials (1)

budesonide (rhinocort) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Diverticulitis (Phase 3)

Proctitis (Phase 2)

Recurrence (Phase 3)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2